Immunosuppressive regimens after a heart transplant can hamper good therapeutic progressions in fibrosis

Focused chemists in lab coats and safety goggles making experiments.

The Yoshinori Yoshida laboratory reports the generation of a platform of human heart organoids derived from iPS cells, which they use to test new therapeutic alternatives on cardiac fibrosis. Their study is published in Frontiers in Cell and Developmental Biology.

Obesity-related gut damage may worsen asthma symptoms

Previous article

How docs should talk about brain atrophy to people with MS

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations